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ABSTRACT 
Synthesis, Characterization and Biological Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepines for 
Cytotoxicity and Serine β-lactamases Inhibition  
by 
Joel K. Annor-Gyamfi 
Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives possess cancerostatic and anti-infective 
properties thus making them candidates of possible antibacterial agents. β-lactam antibiotics are 
vital weapons for the treatment of bacterial infections, but their existence and effectiveness has 
been faced with resistance from β-lactamases. Therefore, the need for new effective 
antimicrobial drugs is very crucial. In this work, we synthesized in high yields, PBD analogs 
1−3, 5 and 7−9 in three to four synthetic steps from commercially available L-proline and isatoic 
anhydride. MTT Assay was employed to test the in vitro cytotoxicity of PBD analogs 1, 2, 5 and 
7 on cancer cell lines including MCF-7, SKBR-3, SKMEL-2, CaCo 2 and Mia Paca. These 
compounds decreased the cell viability of MCF-7 by roughly 20% however, 1 and 5 had no 
effect on the SKMEL-2 cell lines. The inhibitory efficacy of these PBDs were also tested against 
TEM-1 and P99 Serine class A and C β-lactamases.  
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CHAPTER 1 
INTRODUCTION 
Natural Products and Organic Synthesis 
Natural products, also known as secondary metabolites, are organic compounds that are 
synthesized by plants, animals or organisms but are indirectly relevant for their growth and 
development.
1 
Unlike primary metabolites, secondary metabolites are found in only specific 
organisms, or groups of organisms and are characteristic of individual species. Alkaloids are 
usually made of cyclic structures with basic nitrogen atoms and they constitute a subgroup of 
natural products.
1
 Chemical synthesis of natural products, either by semi-synthesis or total 
synthesis has been achieved over the years. The fields of organic, medicinal chemistry and 
chemical biology have seen great prospect and significant development, with natural products 
playing central roles as the source of most challenging synthetic targets. Natural products were 
initially considered to be mere waste products until their valuable properties were identified. 
Many alkaloids have chemical defense strategies against microbes, herbivores and even against 
competing plants due to their neuro or cyto-toxins properties.
1,2
 Nevertheless, several functional 
groups present in alkaloids facilitate their interactions with various biological targets therefore, 
making them potential therapeutic candidates with biological or pharmacological activities in the 
area of disease treatments. Modern natural product-derived drugs can be classified as analgesics, 
anti-infective, cholesterol-lowering etc. Common examples of these drugs are Aspirin (1), 
Pencillin G (2) and Atorvastatin (3) respectively (Figure 1).  
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Figure 1: Examples of natural product-derived drugs.  
 
Natural compounds and alkaloids may have symmetrical and simple structures, as in the 
case of urea (4) or wacky and complex architecture (e.g. manzamine, 5) (Figure 2). Complex 
compounds such as brevetoxin (6) have displayed extreme potency. It is a neurotoxin produced 
by algae and has been found to play significant role in the excessive killings of fish and other 
marine life forms; a phenomenon known as red tide catastrophe.
1,2
 Digitalis (Digoxin) is also a 
very poisonous complex compound however, it’s useful cardiotonic properties are observed 
when consumed in an appropriate amount.
1
 
Nature has been the source of organic molecules for a long period of time until in the 
early nineteenth century when scientist began to explore the chemical synthesis of these natural 
products and their derivatives.
3
 Wöhler's synthesis of urea (4) served as a milestone in chemical 
and biological sciences.
1
 Further synthesis of other natural products proceeded through the 
designed and development of series of synthetic routes. 
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Figure 2: Examples of simple symmetrical and complex wacky structures of alkaloids.
1 
 
[1,4]-Benzodiazepines 
The discovery of the first benzodiazepine core (7) containing compound; Valium 
(diazepam) (8) (Figure 3), in 1955 by Leo Sternbach, resulted in the continued search for further 
benzodiazepine derivatives. Other variants such as Ativan (lorazepam) (9) and Xanax 
(alprazolam) (10) were successfully discovered and have been found to possess significant 
biological activities as tranquilizers.
4
 1,4-benzodiazepine core containing drugs have been known 
to possess anti-anxiety and sedative properties.
5
 Several reports have also shown that 1,4-
benzodiazepines are widely used for the treatment of Central Nervous System (CNS) disorders; 
mainly as anti-convulsant
6
, hypnotic
7
, neuroleptic agents
8
 and muscle-relaxants.
9
 The most 
successful hypnotics are Nitrazepam [e.g. Flunitrazepam, (11)], Flurazepam (12), Temazepam 
(13) and Triazolam (14). These extensive biological properties were established when the ability 
of benzodiazepines to increase the inhibitory effects of the Gamma-Amino Butyric Acid 
(GABA) neurotransmitter was first discovered in 1975.
10
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Figure 3: Benzodiazepine derivatives with significant biological activities as tranquilizers.
4 
 
GABA is an amino acid which acts as the most abundant neurotransmitter in the CNS. It 
primarily promotes calm nervous activity by inhibiting nerve transmission in the vertebrate 
brain.
11
 Benzodiazepine enhances the inhibitory action of GABA by binding to and modulating a 
specific site on the GABA receptor known as the GABAA sub- receptor. Compounds 15, 16, and 
Lotrifiban (17) (Figure 4), have been investigated and found to exhibit tremendous activities 
against respiratory syncytical viral (RSV) infections, protozoal and thrombotic diseases 
respectively. The clinical success of these benzodiazepine derivatives have been reported.
12,13
 In 
addition to the above mentioned biological activities, recent reports have revealed that 1,4-
benzodiazepine and their derivatives show activities as anti-proliferative,
14
 anti-microbial,
15
 anti-
22 
 
inflammatory,
16
 anti-HIV,
17
 anti-plateletanti-ulcer,
18
 cholecystokinin antagonists,
19
 endothelia 
antagonists
20
 and vasopressin antagonists.
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Figure 4: Reported Benzodiazepine derivatives with clinical success as anti-respiratory 
syncytical viral infection, anti-protozoal and anti-thrombotic agents respectively.
4
   
 
In the mid 1950’s, researchers at Hoffman LaRoche coincidentally discovered the first 
synthetic benzodiazepine, chlorodiazepoxide (18), which was later released into the market as 
Librium.
22
 In an attempt to produce a target compound containing a benzoxadiazepine ring 
system (19) from a reaction as part of their search for new tranquilizers (Scheme 1)
23
; 
quinazoline-3-oxides (20) were isolated from the reaction instead of (19) and upon treatment 
with base, (20) unexpected rearrangement occurred which resulted in the formation of the 
biologically active chlorodiazepoxide (18).
1,22 
 
23 
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Scheme 1: Coincidental synthesis of chlorodiazepoxide (18) from quinazoline-3-oxides (20) in 
an attempt to synthesize new tranquilizers such as benzoxadiazepine (19) by researchers at 
Hoffman LaRoche.
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Pyrrolo[2,1-c][1,4]benzodiazepines and their natural occurrence 
Naturally occurring pyrrolobenzodiazepines (PBDs) were first discovered in the cell 
cultures of the Streptomyces species in the 1960s.
24
 The first PBD molecule to be separated and 
characterized was anthramycin. Since then, a number of naturally occurring PBDs have been 
isolated from the Streptomyces species, which include sibiromycin
25
 and tomaymycin,
26
 among 
others.
 
It is presumed that the PBD molecules were evolved by the Streptomyces species as a 
form of chemical defense; however, scientists have made use of their antibiotic properties for the 
treatment of cancer. 
 To date, thirteen natural PBD structures have been isolated from the Streptomyces 
species (Figure 5).
27 
Both anthramycin and sibiromycin were shown to have broad spectrum 
anti-tumor activity in vitro and as a result, they have been tested clinically.
28,29
 Anthramycin 
particularly, was found to have significant cytotoxicity against gastrointestinal, breast cancers, 
lymphomas and sarcomas without having significantly ill effects towards red blood cells; 
however, it’s clinical use was limited due to its cardiotoxicity.
28 
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  Anthramycin (R8=CH3, R9=R1=R2=H) (21)
  Mazethramycin (R8=R1=CH3, R9=R2=H) (22)
  Porothramycin (R8=H, R9=R1=R2=CH3) (23)
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Figure 5: Naturally occurring PBDs isolated from Streptomyces species.
27
  
Pyrrolobenzodiazepines are defined by their tricyclic structure, which is composed of an 
aromatic A-ring, a 1,4-diazepin-5-one B-ring, and a pyrrolidine C-ring. The PBD compounds 
differ from one another by the location and type of substituent groups on all three rings. The 
C11a carbon has an S-configuration, which gives the molecules a right-handed twist. In addition 
to their right handed-twist, it is important to note that the natural PBDs can exist in three 
interchangeable forms at their N10−C11 position: imine, carbinolamine, and carbinolamine 
methyl ether.
27 
PBDs that are produced synthetically can exist as a mixture of two or three of the 
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previously mentioned forms, or exist primarily as one (Scheme 2). The choice of solvent most 
certainly has an effect on which form exists in solution. However, the three interconvertible 
forms are normally considered to be equivalent. In all cases, the C11 position of the PBDs is 
electrophilic.
27,29 
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Scheme 2: Interchangeable forms of PBD in solution at N10−C11 position.
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When considering the interaction between PBDs and DNA, the study of DNA’s helical 
structure is essential. Double-helical DNA is composed of two parts: the major and minor 
grooves. The major groove is wider and deeper in comparison to the minor groove, making it 
more accessible to interacting molecules such as proteins. For this reason, small molecules 
(including many antibiotics) of less than 1000 Da prefer to bind in the minor groove.
27 
Each 
groove contains very specific base pair arrangements, with each base containing hydrogen bond 
donors and acceptors (Figure 6). The differences between the donor and acceptor groups of the 
base pairs, in addition to the size and spacing of the major and minor grooves, opens up the 
possibility of selectivity for drugs.
30,31 
 
26 
 
 
 
Figure 6: Hydrogen bonding between adenosine/thymine (left) and guanosine/cytosine (right) 
base pairs of DNA.
27 
 
PBDs have an S-configuration at carbon C11a which gives the molecules a right-handed 
twist. This right-handed twist offers the PBD the appropriate three-dimensional shape to fit 
snugly within the B-form DNA double helix, enabling them to span three base pairs and 
consequently interfere with DNA processing, as a result of the formation of an adduct in the 
minor groove. Hence, they are classified as useful antitumor agents. A recent study on the 
structure of the anthramycin-DNA adduct has been done by NMR, fluorescence spectroscopy 
and molecular modelling techniques.
26
 A report on the X-ray crystallography data for 
anthramycin methyl ether (21) has revealed that the twist of the molecule is responsible for the 
isohelical interaction of the PBD molecule with the minor groove of the DNA.
36
 In fact, a 
synthetic PBD with R-configuration at C11a was shown to lack DNA binding affinity and in 
vitro cytotoxicity.
32 
The minor groove of DNA is a vulnerable site of attack in that it is normally 
unoccupied; most DNA interactive proteins bind to the major groove, due their bulkiness. This is 
presumably why the Streptomyces species developed PBDs as a means of chemical defense.
33 
27 
 
  As noted before, pyrrolobenzodiazepines have an electrophilic carbon atom at the C11 
position, which, in combination with the right-handed twist of the molecules, allows the PBDs to 
alkylate the nucleophilic NH2 group of the guanine in the minor groove of DNA. DNA 
footprinting studies have shown that the interaction between PBDs and DNA is sequence 
selective, preferentially targeting 5ʹ-Pu-G-Pu sequences. The spanning of three base pairs by the 
adducts confirmed this sequence with a rank order of 5ʹ-Pu-G-Pu > 5ʹ-Pu-G-Py or 5ʹ-Py-G-Pu > 
5ʹ-Py-G-Py sequences (where Pu = purine base, Py = pyrimidine base and G
 
= guanine base).
34,36
 
After insertion in the minor groove, the nucleophilic attack of the exocyclic N
2
 of the guanine 
base at the electrophilic C11 position of the PBD results in the formation of an aminal bond 
(Scheme 3).
35−37
 The covalent bonds that the PBDs form to the exocyclic amino group of the 
guanine base allows the molecules to act as an adduct that blocks biological processes such as 
transcription and RNA polymerase progression.
26
 The cytotoxic/antitumor activities of 
pyrrolobenzodiazepines are attributed to these interactions, however, the relationship between 
DNA-binding affinity, sequence-selectivity and either in vitro cytoxicity or in vivo antitumor 
activity is not completely understood.
36
 Therefore, this area of research has been of great interest 
to most scientists. Thurston and Hurley have proposed structure-activity relationship (SAR) 
predictions based on Corey-Pauling-Koltun (CPK) models.
26,38 
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Scheme 3: Proposed mechanism of PBD’s action in binding to the exocyclic N
2
 of the guanine 
base in the minor groove.
35,36 
  
 After the discovery and elucidation of anthramycin’s structure in 1965, its first total 
synthesis was reported three years later.
 
Since the success of natural PBDs that have significant 
cancer cell cytotoxicity, chemists have synthesized many analogues with hopes of discovering 
new lead compounds with potent anticancer properties and specific sequence recognition.
27,34
 
The goal of these syntheses is to introduce new substituents to the basic structure, and to 
ultimately enhance the cytotoxicity of the PBD molecules. An example of the synthesis of the 
basic structure of a PBD is shown below as Scheme 4: 
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Scheme 4: An example of a synthetic route for the synthesis of the PBD basic structure.
36
  
  
 All natural PBDs that have been isolated from Streptomyces cultures are classified today 
as PBD monomers. Their classification of being monomers has nothing to do with their existence 
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in nature, but rather that all natural PBDs only contain only one unit of the basic structure per 
molecule. Focus on the synthesis and enhancement of PBD monomers came first naturally due to 
the structures of the natural products. 
 Among the natural products, the PBDs which contained endo-exo unsaturation at the C2 
position are the most potent. PBD monomers that have been produced synthetically have 
confirmed that C2-unsaturation (C-ring) enhances in-vitro potency.
24
 More than eighty C2-aryl-
substituents have been synthesized, with carbocyclic and heterocyclic C2-aryl substituents 
ranging from single aryl rings to fused rings systems, which has established the molecular 
requirements of the C-ring for in vitro cytotoxicity.
34 
These structures were so successful that 
two of them were tested in vivo, namely SG2738 (33) and SG2042 (34) (Figure 7).
24
 SG2738 
was tested on a HCT-116 human colon xenograft, but only produced a modest delay in the colon 
tumor growth; SG2042 was tested in six human tumor xenografts, with some antitumor activity 
in renal models and breast cancer models.
34
 The structures of SG2738 and SG2042 are shown 
below: 
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Figure 7: Remarkable in vitro and in vivo cytotoxicity of PBDs with C2-aryl substituents on a 
HCT-116 human colon and tumor xenograft.
34 
 
The other class of the synthetic molecules are PBD dimers. These synthetic molecules are called 
dimers because they contain two complete units of the basic PBD structure, or two monomers. 
The concept and purpose behind the synthesis of the dimers was to generate molecules which 
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contained the PBD antitumor characteristics, but also to span greater length of DNA.
24
 Unlike 
the single PBD unit, studies with NMR and modelling have revealed that PBD dimers span six or 
seven base pairs. In addition, with the increased length and the active constituents of the PBD 
molecules on both ends, the dimers were predicted to form irreversible crosslinks between the 
DNA strands with remarkable cross-linking efficiency and cytotoxicity, especially, dimers linked 
through their C-8 positions.
39 
In the early 1990s, a PBD dimer known as DSB120 (35) (Figure 8) was formed by 
linking two DC81 monomer PBDs through their aromatic A-ring phenol C-8 positions via a 
propyldioxy linker.
24,27 
In comparison to its monomer DC81, the dimer has been shown to have 
increased DNA binding affinity and sequence specificity. The dimers improvement in biological 
activity has been attributed to its ability to form crosslinks on DNA irreversibly due to the 
presence of two active sites on the drugs.
27
 This compound was shown to be highly cytotoxic in 
vitro; however, DSB120’s in vivo studies were not promising. The structure of DSB120 is shown 
below:  
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Figure 8: Example of a PBD dimer with increased DNA binding affinity and sequence 
specificity.
27
 
 
Due to the success of DSB120 in vitro, a second category of PBD dimers were synthesized, 
being modeled after the structure of the natural product tomaymycin, which contains 
unsaturation at the C2 position.
24,27
 As noted before, all of the natural products that contained 
unsaturation at the C2 position were shown to have the highest amount of cytotoxicity in vitro. 
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The efforts to synthesize PBDs shared the characteristics of the relatively successful natural PBD 
products which resulted in the synthesis a dimer by the name of SJG136 (36) (Figure 9). This 
was shown to be significantly more cytotoxic than DSB120, in vitro.
24
 The increased 
cytotoxicity of SJG136 in comparison to DSB120 is attributed to an enhanced ability to form 
DNA crosslinks due to its unsaturation at C2. As a result of impressive in vitro studies, SJG136 
was tested thoroughly in vivo against 10 human tumor xenografts, including but not limited to 
melanomas, ovarian carcinomas, breast cancer, colon cancer, and lung cancer. The SJG136 
compound shown to be active (tumor mass reduction) against all 10 models.
34
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Figure 9: Remarkable in vitro and in vivo cytotoxicity of PBD dimer with C2-aryl 
substituents.
24,27 
 
The impressive and extensive data collected regarding SJG136’s activity in pre-clinical 
trials was the reason for its successful entry into clinical Phase I, testing against advanced solid 
tumors in 2004.
24 
During Phase I of the clinical trials, different dosing schedules were tested to 
determine the best mode of dosing for the drugs. During the most effective dosing schedule, 
SJG136 had promising results. For instance, a patient with malignant melanoma achieved stable 
disease while being treated with SJG136; also, a patient with leiomyosarcoma had stable disease 
for 18 weeks.
24 
In addition,
 
a patient with ovarian carcinoma achieved a 62% decrease in tumor 
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size, lasting for eight months. Due to the success of SJG136 during Phase I clinical trials, the 
compound has recently progressed to Phase II.
34
 
Cancer remains the second major cause of death globally. In 2008, it was accounted for 
the deaths of 7.6 million people. The most extensively characterized panel of cancer cell lines in 
existence is the NCI-60 cell line collection, which consists of 60 human cancer cells. Nine 
different tumor types serve as the source of these cancer cell lines; including leukemia (LN), 
colon (CO), lung [non-small lung cancer (NSCLC)], central nervous system (CNS), renal (REN), 
melanoma (ME), ovarian (OVR), breast (BR) and prostate (PRO).
40
 The third most common 
cause of cancer and the second leading cause of cancer death in Europe and the United States is 
colorectal cancer.
41
 About 5−10% of people with inherited gene defects (mutations) have risks 
for colorectal cancer.
42
 Therefore, the design and development of more potent therapeutic agents 
for cancer is of great concern. 
 
History of β-lactam Antibiotics and β-lactamase Inhibitors 
One of the significant advances in modern medicine has been the development of 
antibiotics.
43
 Innumerable lives have been saved by the use of antibiotics, which still remain the 
backbone of therapy for bacterial infections. The first β-lactam, penicillin G (benzylpenicillin 
(37) [Figure 10]), was discovered by Fleming in 1928, and introduced as a clinical antibacterial 
agent in the early 1950s. Penicillin was of great clinical significance and its success incited the 
exploration for and the development of further derivatives. This pursuit augmented the clinical 
use of β-lactam antibiotics in the present age (penicillins, narrow- and extended-spectrum 
cephalosporins [e.g. Cefotaxime (38)], monobactams [e.g. Aztreonam (39)], and carbapenems 
(40-43) [Figure 10]).
44
 All these classes of antibiotics have a common structural feature, the 
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highly reactive four-membered β-lactam ring. Natural scaffolds produced by microorganisms are 
the source of chemical derivatives of most penicillins and cephalosporins recommended today.
45 
Unfortunately, β-lactamase-mediated resistance to β-lactam antibiotics has posed significant 
clinical threat to these life-saving drugs. Resistant to penicillin emerged after penicillin-resistant 
strains of Staphylococcus aureus (S. aureus) expressing and secreting β-lactamase were isolated. 
The ineffectiveness of penicillin against a significant proportion of S. aureus hospital isolates 
prompted the development of methicillin, a β-lactamase-insensitive semi-synthetic penicillin. 
However, methicillin-resistant strains of Staphylococci aureus (MRSA) were also identified soon 
after methicillin was introduced in clinical practice.
46−48
 Bacteria are constantly developing 
antibiotic-resistance mechanisms to enhance their growth and survival. Therefore, there is an 
ever-present need for new and effective antimicrobial drugs (derivatives). In view of this 
emerging antimicrobial resistance, two major strategies have been advanced to sustain the 
efficacy of β-lactam antibiotics: (i) discover or design β-lactam antibiotics that are able to evade 
bacterial enzymatic inactivation conferred by β-lactamases, or (ii) inhibit β-lactamases so the 
partner, β-lactam can reach the penicillin binding proteins (PBPs), the target of β-lactam 
antibiotics.
49 
Despite the resistance posed by β-lactamases in conjunction with DD-peptidases, 
PBPs still remain attractive targets for antibiotic compounds. 
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Figure 10: Examples of the first generation of β-lactam antibiotics.
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Mechanism of action of β-lactam Antibiotics 
β-lactam antibiotics are vital weapons for the treatment of bacterial infections. They 
demonstrate their bactericidal effects by inhibiting enzymes involved in cell wall synthesis. The 
bacterial cell wall is an integral component that maintains the cell shape of the bacteria in a 
hypertonic and hostile environment.
50
 The rigid cell wall (peptidoglycan) provides the tensile 
strength needed to withstand high osmotic pressures that would otherwise cause the plasma 
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membrane to rupture.
51
 The peptidoglycan is made of alternating N-acetylmuramic acid (NAM) 
and N-acetylglucosamine (NAG) units that are linked by transglycosidases. Each NAM unit is 
further connected to a pentapeptide. The cell wall periplasm of the bacteria contains enzymes 
called DD-transpeptidases, also known as penicillin binding proteins (PBPs) that catalyze the 
transpeptidation reaction, the final stage of cell wall biosynthesis. This reaction involves the 
cross-linking of the two D-alanine-D-alanine NAM pentapeptide that confers the rigidity of the 
cell wall.
52−55
 
The β-lactam rings mimic the structural features of the D-alanine-D-alanine sequence of 
the NAM pentapeptide, thereby acting as a false substrate for the PBPs. The serine residue of the 
PBP form covalent bond with the carboxylate or sulfonate group of the β-lactam antibiotic thus, 
resulting in the acetylation of the DD-transpeptidases (i.e. PBPs). The acylated enzyme is 
inactive and unable to catalyze further transpeptidation reaction. Such a mechanism is called 
suicide inhibition or mechanism-based enzyme inactivation
52 
(Scheme 5). 
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Scheme 5: Transpeptidation reaction of PBP serine residue and suicide inhibition of the reactive 
PBP serine residue by β-lactam substrates.
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Classifications of Penicillin Binding Proteins 
The PBPs are classified as high molecular weight PBPs (HMW-PBPs) and low molecular 
weight PBPs (LMW-PBPs). Further division of the HMW-PBPs gives classes A and B, and the 
LMW-PBPs results in four subclasses basis their tertiary structures. The HMW-PBPs are the 
main target of β-lactam antibiotics because they are responsible for catalyzing the 
transpeptidation reaction that cross-links the glycan strands of the cell wall. Thus, cell survival is 
highly dependent on the HMW-PBPs. However, LMW-PBPs are minor targets of β-lactam 
antibiotics since they are dispensable in laboratory conditions. The formation of the glycan 
chains (transglycosylation) is catalyzed by class A PBPs whereas the cross-linking of 
peptidoglycan stem-peptides (transpeptidation) on the peripheral of the cytoplasmic membrane is 
catalyzed by both class A and class B PBPs. Peptidoglycan is specific to bacteria, and antibiotic 
drugs used to impede its biosynthesis are often than not, less toxic to humans.
56
  
 
Resistant-Mechanisms of bacteria against β-lactam antibiotics 
Bacteria have developed resistant-mechanisms against β-lactam antibiotics in diverse ways:
57 
(i) The most important mechanism of resistance in Gram-negative bacteria involves the 
production of β-lactamases that catalyze the hydrolysis of β-lactam cycle. Rapid 
resistance over a broad range of bacteria is possible by the transfer of plasmid 
encoded β-lactamases.
58 
(ii) An important mechanism of resistance in Gram-positive bacteria [e.g. methicillin-
resistant S. aureus (MRSA)] involves the formation of low-affinity PBPs which 
catalyze the transpeptidation reaction. High concentrations of β-lactam antibiotics 
37 
 
will still remain ineffective due the low affinity nature of the PBPs. The major factor 
that promotes resistance of these microorganisms to β-lactam antibiotics is the 
mutation of residues, which surrounds the active sites of these PBPs. Therefore, 
mutation of residues is the mainstay for PBPs’ low-affinity to β-lactams. Generally, 
the class B PBPs which are involved in cell division (homologous to Escherichia coli 
PBP3) are affected by this mechanism since they are the main targets of β-lactam in 
these microorganisms.
56
 Mutations have been found in microorganisms such as S. 
pneumoniae PBP2X
59
, Neisseria gonorrhoeae PBP2
60
 and Haemophilus influenza 
PBP3.
61
 Again, dissemination of resistance to β-lactams can occur by horizontal gene 
transfer. For example, resistance in Streptococci is disseminated via natural 
transformation
62
, and transduction of the mecA gene (coding for the methicillin-
resistant PBP2a protein) into the chromosome of S. aureus is also the source of 
resistance in MRSA.
58, 63
 
(iii) Outer membrane proteins (OMPs) allow the transfer of β-lactams through the outer 
membrane. As the production of the OMPs decrease, considerable decrease in the 
effective concentration of antibiotics in the periplasm is also observed thus, an 
increase in minimum inhibitory concentration (MIC) values. The combination of this 
mechanism with another resistance mechanism such as the expression of a β-
lactamase, results in resistant phenotype.
64,65
 
(iv) The effective concentration of β-lactam antibiotics in the periplasm of Gram-negative 
bacteria can also be decreased by efflux pumps. β-lactams can be exported outside the 
cells through the outer membrane by the efflux pumps in the microorganisms.
65
  
38 
 
The emergence of β-lactam resistance has prompted the development of series of strategies to 
combat this life-threatening issue. The quest for new antibiotics and β-lactamase inhibitors has 
been consistent from the beginning but after 60 years, the legitimate clinical use of antibiotics 
has declined due to the progressively insensitive nature of some bacterial strains to almost all 
clinically useful β-lactams.
66,67
 The misuse and overuse of antibiotics, including utilization to 
promote growth in farm animals, is a major factor to the tremendous increase in this trend.
68
 The 
zeal of pharmaceutical companies to maintain research programs in this area has declined due to 
the rapid development of resistance within the last two decades. Thus, most of the major 
companies have nearly empty antibiotic discovery pipelines.
69,70
 There has been a 
recommendation that the dissemination of resistance, in relation to the magnitude to the selective 
pressure can be reduced by the careful usage of limited amount of antibiotics in the environment 
and the food chains.
71
 
 
Classification of β-lactamases  
β-lactamase enzymes are categorized based on two major classification schemes:  
(i) The Ambler Classes A through D, which is based on amino acid sequence homology, and  
(ii) The Bush-Jacoby-Medeiros groups 1 through 4, is based on substrate and inhibitor 
profile.
72,73
  
Classes A, C, and D, are serine β-lactamases and they hydrolyze β-lactams antibiotics in a 
similar fashion due to their structural similarities. However, Class B β-lactamases are termed 
metallo-β-lactamases (MBLs) due to the presence of either a single Zn
2+
 ion or a pair of Zn
2+
 
ions coordinated to His/Cys/Asp residues in the active site.
74
 
In this literature review, the Ambler classification scheme has been employed. 
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Class A serine β-lactamase 
In general, most class A enzymes except K. pneumoniae carbapenemase (KPC), are susceptible 
to the most commercially available β-lactamase inhibitors like clavulanate.
75
  
Class A extended-spectrum β-lactamases (ESBLs) 
This class of β-lactamases hydrolyze many of the oxyimino-cephalosporins, monobactam and 
carbapenems.
76,77
 
Class A serine carbapenemases  
These β-lactamases include the non metallo carbapenamase of class A (NMC-A), IMI, SME, and 
KPC. They are responsible for the hydrolysis of first generation β-lactams such as carbapenems, 
cephalosporins, penicillins, and aztreonam. This class of β-lactamases have been observed to be 
predominant in Enterobacter cloacae, Serratia marcescens, and K. pneumoniae.
78
  
Class B metallo-β-lactamases  
These β-lactamases enzymes depend on Zn
2+
 thus, their mode of hydrolysis of β-lactam 
antibiotics is different from the other classes of β-lactamases (A, C, and D). They hydrolyze and 
exhibit high resistance to cephalosporins, carbapenems, penicillins, and the clinically available β-
lactamase inhibitors.
 73,79
  
Class C serine cephalosporinases  
Class C serine cephalosporinases are mostly encoded in the bla gene of bacteria chromosomes. 
Organisms that express this β-lactamase are typically resistant to penicillins, β-lactam β-
lactamase inhibitor combinations, and cephalosporins, including cefoxitin, cefotetan, ceftriaxone, 
and cefotaxime. However, AmpC enzymes, an example of this class of serine β-lactamase are 
known to be inhibited by cloxacillin, oxacillin, and aztreonam.
73,80
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Class D serine oxacillinases 
In contrast to the relatively slow hydrolysis of oxacillin by classes A and C, class D serine β-
lactamases hydrolyze oxacillin at a faster rate of at least 50%. Due to this ability, they were at 
first termed as “oxacillinases”. They exhibit resistance to carbapenems, cephalosporins, and 
penicillins.
81
 
 
Evolution of β-lactam and non-β-lactam β-lactamases inhibitors 
Since 1970, some inactivators and “suicide inhibitors” of class A β-lactamases have been 
introduced in clinical medicine. These β-lactamases inhibitors including clavulanic acid (44), 
tazobactam (45) and sulbactam (46) (Figure 11), have common structural features, the highly 
reactive four-membered β-lactam ring. Report shows that when these β-lactamase inhibitors 
were combined with β-lactam antibiotics (amoxicillin/clavulanate: Augmentin
TM
, 
ampicillin/sulbactam: Unasyn
TM
, piperacillin/tazobactam: Zosyn
TM
), they efficiently lowered the 
MICs of the β-lactam antibiotics against various bacteria. However, after several years of 
success, these combination drugs faced resistance from the production of inhibitor resistant β-
lactamases or enzyme hyper production was observed.
57
 Many β-lactams and non-β-lactams β-
lactamase inhibitors have been developed during the last 40 years.
57,82,83
 NXL104 (avibactam) 
(Figure 11) being the first non-β-lactam serine β-lactamase inhibitor to be studied in clinical 
trials since the introduction of tazobactam (Figure 11).
70
 Combination of this non-β-lactam 
antibiotic with extended-spectrum beta-lactamases (ESBL) such as cephalosporins and 
aztreonam increases its potency against Gram-negative infections (including Klebsiella).
84−86
  
During the last decade, development of some new β-lactam antibiotics has been observed and 
their clinical trials have also currently been conducted.
70,87,88
 Doripenem (Figure 10) has been 
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reported to exhibit potential inhibition against complicated urinary tract infections and intra-
abdominal infections.
70
 It is stable to hydrolysis by many β-lactamases except class B metallo-β-
lactamases and serine carbapenemases.
89
 BAL30072 (48) (Figure 11) is a new β-lactamase 
stable monobactams with activeness against Gram-negative pathogens that are responsible for 
the production of resistant β-lactamases (ESBL and metallo-β-lactamases). Ceftobipole (50) 
(Figure 11), a novel cephalosporin, is very active against a wide range of Gram-negative 
(including Pseudomonas aeruginosa) and Gram-positive pathogens (including MRSA and 
penicillin-resistant S. pneumoniae).
90
 It is stable to hydrolysis by some β-lactamases (non-ESBL 
class A) except ESBLs and carbapenemases. 
Ceftaroline (49) (Figure 11) is effective for the treatment of acute bacterial skin and skin 
structure infections and community-acquired bacterial pneumonia. It has significant activities 
against the MRSA and multi-drug resistant S. pneumoniae and common Gram-negative 
pathogens.
91
 In synergy with tazobactam, its activities against some multi-drug resistant as ESBL 
producing E. coli and Klebsiella pneumoniae is enhanced.
92 
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Figure 11: β-lactam based β-lactamase inhibitors and examples of new β-lactam antibiotics.
37-40 
The above examples confirm that when the parent structure of traditional β-lactam is 
modified, new molecules of significant activities against resistant pathogens are discovered. 
Recent reports show that some non-traditional β-lactams (large ring 1,3-bridged 2-azetideiones) 
with significant activities against PBP2a of a MRSA have been synthesized.
93-96
 
Unfortunately, some of these molecules are hydrolyzed by β-lactamases. Therefore, their 
efficiency is enhanced only when combined with a β-lactamase inhibitor. Non-β-lactam 
inhibitors of PBPs are better alternatives for the resistance of β-lactamase than β-lactam because 
their characteristic features make it impossible for β-lactamases to recognize them as substrates. 
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During the last three decades, researchers had worked with much effort to find non-β-lactam 
inhibitors that can substitute β-lactams in clinical practice. However, to date, NXL104 seems to 
be the only non-β-lactam β-lactamase inhibitor that has been studied in clinical trials.
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Justification of Research 
Our primary reason for exploiting PBDs as potential non-β-lactam TEM-1 and P99 Serine 
class A and C β-lactamase inhibitors emerged from the fact that the active regions of typical β-
lactam β-lactamase inhibitors are synonymous with the PBD core structure. From a theoretical 
perspective, when a bond in a regular β-lactam ring is broken, a new structure that is analogues 
to the PBD core structure but with the same active sites as that of a regular β-lactam β-lactamase 
inhibitor can be obtained (Scheme 6a). Thus, our goal was to synthesize PBD analogs and 
evaluate them as possibly potential non-β-lactam β-lactamase inhibitors. In addition, PBDs could 
act as suicide inhibitors against serine β-lactamase in the sense that an attack on the PBD 
carbonyl carbon by the Ser-OH of the active site of serine β-lactamase could possibly result in 
the formation of a very stable covalent bond (Scheme 6b). Thus, unlike the other serine β-
lactamase inhibitors, this stable bond with the PBD carbonyl carbon inactivates the serine β-
lactamase making it impossible to further hydrolyze the β-lactam antibiotics which could be used 
in combination with the PBD analogs. The mode of action of clavulanic acid, a classic β-lactam 
β-lactamase inhibitor, in relation to the possible mechanism of action of suicide inhibitors is 
shown in (Scheme 6c) below.  
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Scheme 6a: Structure based relationship between β-lactam β-lactamase inhibitors and PBDs. 
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Scheme 6b: Proposed mechanism of action of PBDs as non-β-lactam β-lactamase suicide 
inhibitors  
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Scheme 6c: Mechanism of action of β-lactam β-lactamase inhibitors (suicide inhibitors) 
(Adapted from http://wizard.pharm.wayne.edu/medchem/betalactam.html). 
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Statement of Work 
In this research, synthesis and structure-activity relationship (SAR) studies of PBD analogs, 
and further optimization of established leads was the basis of our research plan to produce novel 
PBDs as potential anti-cancer agents with minimal toxicity to normal human cells and to 
establish a new family of highly effective TEM-1 and P99 Serine class A and C β-lactamase 
inhibitors. Novel PBD analogs 3, 7−9 were synthesized in three to four steps from commercially 
available L-proline and isatoic anhydride. 
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CHAPTER 2 
RESULTS AND DISCUSSIONS 
Chemistry 
Syntheses of Pyrrolobenzodiazepine (PBD) derivatives 
 The synthesis of all derivatives were accomplished with the readily available basic 
structure of PBD natural product (1) (from Isatis indigotica
97
) used as the starting material. 
 
Synthesis of (S,E)-11-(propylimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-
a][1,4]diazepin-5-one (3) 
Procedures from literature
36,98,99
 were followed for the synthesis of compound 1 by the 
cyclocondensation of equimolar of isatoic anhydride with L-proline in DMF for 5 hours 
(Scheme 7). Upon recrystallization from Acetone/DMF (10:1 v/v) to obtain 82% yield, 
1
H NMR 
in DMSO-d6 showed 12 signals; a singlet for the (N-H) group at 10.51 ppm, two each of 
doublet-doublet and doublet-doublet-doublet for the aromatic protons between 7.79−7.11 ppm, a 
doublet for the 11aH between 4.10−4.14 ppm, and six multiplets for the three (−CH2) groups on 
the pyrrolidine ring between 1.78−3.59 ppm (refer to spectra at Appendix A1−A3) instead of 
three signals which were expected. Further splitting of the individual multiplets is therefore the 
reason for a total of six multiplets from the pyrrolidine ring.  The individual peaks were 
integrated to give approximately 1:1:1:1 ratio for the aromatic protons and 1 for the 11aH 
doublet peak. 
13
C NMR also showed 12 expected peaks with the characteristic secondary (2
0
) 
and tertiary (3
0
) amide carbons at 171.315 and 165.090 ppm (C=O) respectively. The 6 aromatic 
carbon peaks were between 121.832−136.957 ppm and the C11a gave a peak at 56.772 ppm. The 
three (−CH2) groups on the pyrrolidine ring also gave the following peaks; 47.435, 26.338, 
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23.638 ppm (refer to spectrum at Appendix A4). C-DEPT 135 analysis also confirmed the 
number of methylene (−CH2) and methine (C-H) groups in the structure. The spectrum showed 3 
negative signals for the three (−CH2) groups on the pyrrolidine ring and 5 positive signals for the 
methine groups; 4 sp
2
 (C-H) groups on the aromatic ring and a C11a signal. However, quaternary 
(4
0
) carbons were invisible in the spectrum (refer to spectrum Appendix A5). The GC-MS 
analysis of compound 1 in chloroform gave the molecular ion peak at m/z = 216.0 u and a base 
peak at m/z = 70.0 u (refer to Appendix A6). IR analysis gave peaks at 3350 cm
-1
, 2850−2955 
cm
-1
 and 1679 cm
-1
 for the 2
0
 amide, C-H and the C=O stretching respectively (refer to spectrum 
on Appendix A7). At 25
 o
C, 5 mg of Compound 1 in 1 mL methanol rotated plane polarized 
light through a 0.1 dm tube length in the positive direction at an angle of 512
o
.
 
 
Monothionation of compound 1 with 2,4-bis-(4-methyoxyphenyl)-1,3-dithia-2,4-
diphosphetane-2,4-disulfide (Lawesson’s reagent) in THF at room temperature for 28 hours
36,100
 
resulted in the formation of compound 2 as a yellow solid in good yield (Scheme 7). 
1
H NMR, 
13
C NMR and C-DEPT 135 spectra in DMSO-d6 showed signals similar to compound 1 except 
that the 
13
C NMR spectrum gave characteristic peaks at 202.568 ppm for (C=S) and 164.746 for 
ppm (C=O) of the 3
0
 amide, which were different from that shown by compound 1 (refer to 
spectra on Appendix B1−B5). The GC-MS analysis of compound 2 in chloroform gave the 
molecular ion peak at m/z = 232.0 u and a base peak at m/z = 70.0 u (refer to spectrum on 
Appendix B6). IR analysis gave stretching peaks at 3125 cm
-1
, 2974 cm
-1
 and 1679 cm
-1
 for the 
N-H, C-H and the C=O (for amide) respectively (refer to spectrum on Appendix B7). At 25
 o
C, 5 
mg of Compound 2 in 1 mL chloroform rotated plane polarized light through a 0.1 dm tube 
length in the positive direction at an angle of 762
o
. 
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Scheme 7: Synthesis of PBD Dilactam (1) and Thiolactam (2). 
 The cyclic amidine (3) was synthesized in high yields by refluxing the monothiolactam 
(2) with propyl amine in the presence of mercury (II) chloride for an hour (Scheme 8).
 
The 
proposed mechanism for this reaction is shown in Figure 12. 
1
H NMR of compound 3 in CDCl3 
showed 13 signals; a doublet, two doublet-doublets and a doublet-doublet-doublet for the 
aromatic protons between 7.03−7.93 ppm, a doublet-doublet for the 11aH between 4.01−4.04 
ppm and four multiplets for the three (−CH2) groups on the pyrrolidine ring between 2.20−3.90 
ppm instead of three signals which were expected. Further splitting of an individual multiplet is 
therefore the reason for a total of four multiplets from the pyrrolidine ring. The individual peaks 
were integrated to give approximately 1:1:1:1 ratio for the aromatic protons and 1 for the 11aH 
doublet-doublet peak. Also, the (−CH3) and the two (−CH2) groups on the propyl amine chain 
gave their respective proton NMR signals in the order; triplet, multiplet and multiplets, with 
corresponding shifts between 0.96−0.99, 1.60−1.69 and 1.99−2.12 ppm.  (refer to spectra at 
Appendix C1−C4). 
13
C NMR also showed 15 expected peaks with the characteristic (C-N) and 
tertiary (3
0
) amide (C=O) peaks at 156.426 and 166.795 ppm respectively. The 6 aromatic 
carbon peaks were between 122.832−147.709 ppm and the C11a gave a peak at 54.486 ppm. The 
three (−CH2) groups on the pyrrolidine ring also gave the following peaks; 26.705, 43.283 and 
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46.472 ppm. Again, 3 signals; 11.679, 22.277 and 23.929 ppm, were observed for the three 
carbons on the propyl group (refer to spectrum at Appendix C5). The GC-MS analysis of 
compound 3 in chloroform gave the molecular ion peak at m/z = 257.0 u and a base peak at m/z = 
70.0 u (refer to spectrum on Appendix C6). IR analysis gave peaks at 3356 cm
-1
, 2880−2941 
cm
-1
 and 1731 cm
-1
 for the (N-H), (C-H) and (C=O) stretching respectively (refer to spectrum on 
Appendix C7). At 25
 o
C, 5 mg of Compound 3 in 1 mL chloroform rotated plane polarized light 
through a 0.1 dm tube length in the positive direction at an angle of 1106
o
. 
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Scheme 8: Synthesis of PBD cycloamidines (3). 
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Figure 12: Proposed mechanism for the synthesis of PBD cycloamidine (3). 
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Synthesis of 5,6-Dihydro-4H-3-thia-6a,11b-diazabenzo[g]cyclopenta[e]azulene-1,7-dione (4) 
 Procedures from literature
36
 were followed for the synthesis of the tetracyclic PBD 
analog (4). The cyclization reaction between a solution of thiolactam (2) in anhydrous THF and 
freshly prepared α-bromoacetyl chloride proceeded under nitrogen for 15 h at room temperature 
to afford a yield of 75% (Scheme 9). This reaction involved the removal of the C-11a proton to 
form an sp
2
 bond between the C-11a and electrophilic C-11 carbons. Thus, compound 4 does not 
rotate plane polarized light. Comparing the 
1
H-NMR spectra of compound 4 to that of the 
starting material, thiolactam (2) (refer to spectra on Appendix B1−B5), confirmed the 
disappearance of the C-11a proton in compound 4, which was present in compound 2 as a 
doublet peak at 4.28 ppm.  Again, 
13
C-NMR of compound 4 showed two extra carbon peaks at 
172.7 ppm for the carbonyl (C=O) and 50.1 ppm for the (−CH2) group on the 5-membered ring 
of compound 4. The proposed mechanism for this reaction is shown in Figure 13 below.  
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Scheme 9: Synthesis of PBD thiazulene (4).
36 
51 
 
N
N
O
N
N
S
O
H
S
O
Cl
O
Br
H
N
N
S
O
H
Cl
O
N
N
O
H
S
O
Cl
N
N
O
S
O
H
Cl  
Figure 13: Proposed mechanism for the synthesis of PBD thiazulene (4). 
 
Synthesis of (S,E)-11-(hydroxyimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-
a][1,4]diazepin-5-one (5) 
Protocol used for the synthesis of compound 5 was similar to that reported by Rekowski 
et al. 2010 and Bartsch et al. 1989
101,102
 except that a slight modification was employed which 
resulted in a significant yield of 82% as against 76% reported in literature.
101
 The use of K2CO3 
in place of triethyl amine, as a base for the reaction is the reason for such a drastic change in 
yield. The reaction of compound 2 with hydroxylamine hydrochloride (NH2OH.HCl) under basic 
conditions results in the formation of compound 5 (Scheme 10).  
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Scheme 10: Synthesis of PBD Oxime (5).
91,92 
 
The effective neutralization of the HCl by K2CO3 was of prime importance in that it allowed the 
hydroxylamine (NH2OH) to react easily with the thiolactam (2) which resulted in the formation 
of the oxime (5). The product formed after 24 hours of stirring at room temperature was 
recrystallized from nitromethane to afford compound 5 as yellow needle-like crystals. 
1
H NMR 
in DMSO-d6 showed 10 signals; a singlet at 10.08 ppm for (O-H), a singlet at 8.75 ppm for (N-
H), two each of doublet and triplet for the aromatic protons between 6.89−7.95 ppm, a doublet-
doublet for the 11aH between 4.31−4.33 ppm and three expected multiplets for the three (−CH2) 
groups on the pyrrolidine ring between 1.96−3.86 ppm. The individual peaks were integrated to 
give approximately 1:1:1:1 ratio for the aromatic protons and 1 for the 11aH doublet-doublet 
peak (refer to spectra at Appendix D1−D5). 
13
C NMR in CDCl3 also showed 12 expected peaks 
with the characteristic (C-N) and tertiary (3
0
) amide (C=O) peaks at 151.188 and 166.214 ppm 
respectively. The 6 aromatic carbon peaks were between 120.509−136.881 ppm and the C11a 
gave a peak at 54.440 ppm. The three (−CH2) groups on the pyrrolidine ring also gave the 
following peaks; 23.394, 25.917 and 47.412 ppm (refer to spectrum at Appendix D6). The GC-
MS analysis of compound 4 in chloroform gave the molecular ion peak at m/z = 232.0 u and a 
base peak at m/z = 70.0 u (refer to spectrum at Appendix D7). IR analysis gave peaks at 3281 
cm
-1
, 2878−2965 cm
-1
 and 1612 cm
-1
 for the (N-H), (C-H) and the (C=O) stretching respectively 
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(refer to spectrum at Appendix D8). At 25
 o
C, 5 mg of Compound 5 in 1 mL chloroform rotated 
plane polarized light through a 0.1 dm tube length in the positive direction at an angle of 488
o
. 
 
Synthesis of (S,E)-11-hydrazono-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-
a][1,4]diazepin-5-one (6)  
Procedures from literature
103
 were followed for the synthesis of compound 6 by stirring a 
mixture of compound 2 and 98% hydrazine monohydrate in absolute ethanol at room 
temperature for 15 hours. After the solvent was removed in vacuo, the residue was taken up in 
water and the precipitate was collected, dried and washed with diethyl ether to afford compound 
6 as an off-white solid. Compound 6 was then used as starting material for the synthesis of novel 
triazolo PBDs 7 and 8 in high yields (Scheme 11). 
1
H NMR of compound 6 in CDCl3 gave the 
following signals; a doublet, triplet and two doublet-doublet peaks for the aromatic protons 
between 6.84−7.91 ppm, a broad singlet peak for the (N-H) group at 7.28 ppm, a doublet for the 
11aH between 4.25−4.27 ppm, and six multiplets for the three (−CH2) groups on the pyrrolidine 
ring between 1.89−3.75 ppm (refer to spectra at Appendix E1−E3) instead of three signals 
which were expected. Further splitting of the individual multiplets is therefore the reason for a 
total of six multiplets from the pyrrolidine ring.  The individual peaks were integrated to give 
approximately 1:1:1:1 ratio for the aromatic protons and 1 for the 11aH doublet-doublet peak. 
13
C NMR also showed 12 expected peaks with the characteristic peaks at 166.207 for (C=O) and 
152.152 for (C-N) ppm. The 6 aromatic carbon peaks were between 119.744−137.768 ppm and 
the C11a gave a peak at 55.495 ppm. The three (−CH2) groups on the pyrrolidine ring also gave 
the following peaks; 23.401, 26.093 and 47.328 ppm (refer to spectrum at Appendix E4). IR 
analysis gave peaks at 3484 cm
-1
, 2871−2949 cm
-1
 and 1689 cm
-1
 for the (N-H), (C-H) and the 
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(C=O) stretching respectively (refer to spectrum at Appendix E5). At 25
 o
C, 5 mg of Compound 
6 in 1 mL methanol rotated plane polarized light through a 0.1 dm tube length in the positive 
direction at an angle of 552
o
. 
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Scheme 11: Synthetic route for the formation Triazolo PBDs 7 and 8. 
 
Synthesis of (S)-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-
c][1,4]diazepine-3,9(2H)-dione (7) 
Carbonylation of PBD hydrazinyl lactam (6) with 1,1
’
-carbonyldiimidazole (CDI) in 
dioxane under reflux for 24 hours resulted in the formation of compound 7 as a crude product 
(Scheme 11). Further purification by flash gel column chromatography, using gradient elution 
approach with ethyl acetate and hexane as solvent mixture in the ratios of 1:1, 2:1 and 4:1 
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afforded pure compound 7 as white crystals. 
1
H NMR of compound 7 in CDCl3 showed 11 
signals; a broad, singlet peak at 9.90 for N-H, a doublet, doublet-doublet and two doublet-
doublet-doublet peaks for the aromatic protons between 7.43−8.04 ppm, a doublet-doublet for 
the 11aH between 4.52−4.54 ppm and five multiplets for the three (−CH2) groups on the 
pyrrolidine ring between 2.06−3.89 ppm instead of three multiplet signals which were expected. 
Further splitting of individual multiplet is therefore the reason for a total of five multiplets from 
the pyrrolidine ring. The individual peaks were integrated to give approximately 1:1:1:1 ratio for 
the aromatic protons and 1 for the 11aH doublet-doublet peak (refer to spectra at Appendix 
F1−F3). 
13
C NMR also showed 13 expected peaks with the characteristic secondary (2
0
) and 
tertiary (3
0
) amide (C=O) peaks at 164.746 and 153.918 ppm respectively whiles the 
electrophilic C11 carbon gave a peak at 153.054 ppm and the 6 aromatic carbon peaks were 
between 123.002−132.308 ppm and the C11a gave a peak at 147.327 and 54.486 pm. The three 
(−CH2) groups on the pyrrolidine ring also gave the following peaks; 23.501, 26.009 and 46.472 
ppm (refer to spectrum at Appendix F4). The GC-MS analysis of compound 7 in methanol gave 
the molecular ion peak at m/z = 256.0 u and a base peak at m/z = 43.0 u (refer to spectrum at 
Appendix F5). IR analysis gave peaks at 3356 cm
-1
, 2878−2999 cm
-1
 and 1711 cm
-1
 for the (N-
H), (C-H) and the (C=O) stretching respectively (refer to spectrum at Appendix F6). At 25
 o
C, 5 
mg of Compound 7 in 1 mL DMSO rotated plane polarized light through a 0.1 dm tube length in 
the positive direction at an angle of 136
o
.  
X-Ray structural analysis of(S)-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-
a][1,2,4]triazolo[3,4-c][1,4]diazepine-3,9(2H)-dione (7): Slow evaporation of a saturated 
solution of compound 7 in ethyl acetate/hexane (4:1 v/v) afforded white single crystals with a 
monoclinic unit cell. The molecular construction and the crystallographic numbering are shown 
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in (Figure 14). The 6:7:5 pyrrolobenzodiazepine ring system adopts a twisted conformation, 
with the 7-membered ring adopting a boat arrangement. This finding agrees with the dihedral 
angles of N(2)-C(8)-C(9)-N(1) and N(1)-C(1)-C(2)-C(7) (refer to table at Appendix F7) which 
were determined to be 58.5(2)
o
 and 38.6(2)
o
 respectively. This observation was further 
confirmed by the torsion angles of C(9)-N(1)-C(1)-C(2) with − 6.0(2)
o
 and C(1)-C(2)-C(7)-N(2) 
with − 2.5(2)
o
 (refer to table at Appendix F7). The bond distance of C(8)-N(3) which was 
determined to be 128.8 pm corresponds to the imino C(sp
2
)=N(sp
2
) double bond. Conversely, the 
N(2)-C(8) is a single bond with a distance of 136.9 pm. Again, the presence of a distinct C(8)-
C(9) single bond with a distance of 149.96 pm, unambiguously excludes any tautomerization of 
C(9)-H(9) hydrogen which could result in the formation of an optically inactive tautomer. 
 
 
C(8)–N(3) = 128.8 pm 
N(2)–C(8) = 136.9 pm 
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Figure 14: X-ray diffraction ORTEP structure and cell unit of PBD (7). 
 
Synthesis of (13aS)-3-mercapto-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-
a][1,2,4]triazolo[3,4 -c][1,4]diazepin-9-one (8) 
Thionylation of PBD hydrazinyl lactam (6) with 1,1
’
-thiocarbonyldiimidazole (TDI) 
under the same reaction conditions as described above in Scheme 11, resulted in the formation of 
crude product of compound 8.  Further purification by flash gel column chromatography, using 
gradient elution approach with acetone and hexane as solvent mixture in the ratios of 10:1, 20:1 
v/v, afforded pure compound 8 as brown crystals. 
1
H NMR of compound 8 in CDCl3-d6 showed 
11 signals; a broad, singlet peak at two each of doublet-doublet and doublet-doublet-doublet 
peaks for the aromatic protons between 7.52−8.39 ppm, a doublet-doublet for the 11aH between 
4.54−4.57 ppm and five multiplets for the three (−CH2) groups on the pyrrolidine ring between 
2.09−3.86 ppm instead of three multiplet signals which were expected. Further splitting of 
individual multiplet is therefore the reason for a total of five multiplets from the pyrrolidine ring. 
There was also a broad singlet peak for (S-H) between 1.76−1.89 ppm when CDCl3 was used as 
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the solvent for the 
1
H NMR analysis however, the peak was invisible in DMSO-d6. This 
suggests that the (S-H) proton was easily exchangeable by the residual water in DMSO-d6. The 
exchangeable quality of the acidic proton on the (S-H) is also the reason for the broad peak 
between 1.76−1.89 ppm. The individual peaks were integrated to give approximately 1:1:1:1 
ratio for the aromatic protons and 1 for the 11aH doublet-doublet peak (refer to spectra at 
Appendix G1−G3). 
13
C NMR in CDCl3 also showed 13 expected peaks with the characteristic 
secondary tertiary (3
0
) amide (C=O) and (C-S) peaks at 163.989 and 167.660 ppm respectively. 
The electrophilic C11 carbon gave a peak at 153.054 ppm and the 6 aromatic carbon peaks were 
between 126.168−131.452 ppm with a peak at 51.572 ppm for C11a as well. The three (−CH2) 
groups on the pyrrolidine ring also gave the following peaks; 23.646, 26.674 and 47.535 ppm 
(refer to spectrum at Appendix H4 and H5). The GC-MS analysis of compound 8 in chloroform 
gave the molecular ion peak at m/z = 272.0 u as a base peak (refer to spectrum at Appendix H8). 
IR analysis gave peaks at 3280 cm
-1
, 2880−2989 cm
-1
 and 1680 cm
-1
 for the (N-H), (C-H) and 
the (C=O) stretching respectively (refer to spectrum at Appendix H8). At 25
 o
C, 5 mg of 
Compound 8 in 1 mL chloroform rotated plane polarized light through a 0.1 dm tube length in 
the positive direction at an angle of 37.5
o
. 
 
Synthesis of (S)-7-nitro-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-
5,11(10H)-dione (9) 
Procedures from literature
104
 were followed for the synthesis of compound 9 by stirring a 
mixture of compound 1 and concentrated nitric acid in concentrated sulfuric acid at 0 
o
C for 2 
hours. After quenching with ice, the precipitate was recrystallized from methanol to afford 77% 
of compound 9 as yellow crystals (Figure 15). The synthetic route for constructing the nitro-
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PBD (9) is illustrated in Scheme 12 with the proposed mechanism for this reaction shown in 
Figure 16 as well. 
1
H NMR of compound 9 in CDCl3 gave signals as follows; a singlet peak for 
2
0
 amide (N-H) at 9.39 ppm, two doublet peaks and a singlet peak for the aromatic protons 
between 7.20−8.29 ppm, a doublet for the 11aH between 4.12−4.14 ppm, and the peaks for the 
three (−CH2) groups on the pyrrolidine ring were between 1.89−3.75 ppm (refer to spectra at 
Appendix H1−H3). The disappearance of one aromatic proton and the pattern of splitting of the 
remaining three aromatic protons suggest the nitration of the aromatic ring at position para to the 
2
0
 amide group. The individual peaks were integrated to give approximately 1:1:1 ratio for the 
aromatic protons and 1 for the 11aH doublet-doublet peak.
 13
C NMR in CDCl3 also showed 13 
expected peaks with the characteristic secondary (2
0
) and tertiary (3
0
) amide (C=O) peaks at 
170.971 and 163.484 ppm respectively. The electrophilic C11 carbon gave a peak at 144.490 
ppm and the 6 aromatic carbon peaks were between 122.031−140.307 ppm with a peak at 56.807 
ppm for C11a as well. The three (−CH2) groups on the pyrrolidine ring also gave their signals as 
follows; 23.646, 26.674 and 47.535 ppm (refer to spectrum at Appendix H4 and H5). IR 
analysis gave peaks at 3363 cm
-1
, 2719−2943 cm
-1
 and 1703 cm
-1
 for the amine (N-H), (C-H) 
and (C=O) stretching respectively (refer to spectrum at Appendix H6). At 25
 o
C, 5 mg of 
Compound 9 in 1 mL chloroform rotated plane polarized light through a 0.1 dm tube length in 
the positive direction at an angle of 744
o
. 
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Figure 15: Crystals of nitro PBD (9) from methanol. 
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Scheme 12: Synthetic route for the formation of nitro PBD (9). 
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Figure 16: Proposed mechanism for the mononitration of PBD 1. 
 
Biological Activity 
In vitro Cytotoxicity Evaluation of PBD Analogs 
MTT Assay was employed to test for the in vitro cytotoxicity of PBD analogs 1, 2, 5 and 
7 on cancer cell lines which were obtained from the American Tissue Type Culture Collection 
(ATTC). These cell lines include MCF-7 (Breast), SKBR-3 (Breast), SKMEL-2 (Melanoma), 
CaCo 2 (Colon) and Mia Paca (Pancreatic) and they all differ by tissue type and origin of the 
cells. All PBDs were dissolved in DMSO, and added at 100 µM. Negative controls (only 
containing DMSO) were used as a reference for 100% cell viability. All experiments were 
performed in triplicate and the results are shown in Table 1 and Figure 17 below. The 
compounds decreased the cell viability of MCF-7 by roughly 20%, however, only 1 and 5 had 
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any effect on the SKMEL-2 cell lines. Compounds 2 and 5 also had noticeable effects on 
multiple cell lines. 
 
Table 1: The cytotoxicity assay (%) of PBD analogs 1, 2, 5 and 7 relative to control (100%) 
against SKBR-3, MCF-7, SKMEL-2, CaCo 2, HCT 116 and Mia Paca cell lines. 
PBDs 
SKBR-3 
(Breast) 
MCF-7 
(Breast) 
SKMEL-2 
(Melanoma) 
CaCo 2 
(Colon) 
HCT 116 
(Colon) 
Mia Paca 
(Pancreatic) 
1 92.47 79.72 79.92 92.89 110.98 108.75 
2 97.91 82.29 129.84 89.69 128.28 113.21 
5 113.83 77.05 88.61 93.96 
7 95.79 82.97 115.59 109.18 
Standard Deviation 
PBDs 
SKBR-3 
(Breast) 
MCF-7 
(Breast) 
SKMEL-2 
(Melanoma) 
CaCo 2 
(Colon) 
HCT 116 
(Colon) 
Mia Paca 
(Pancreatic) 
1 10.76 9.44 8.16 3.16 8.56 7.32 
2 3.75 4.40 25.95 6.01 7.06 8.35 
5 12.77 2.72 10.04 3.88 
7 11.93 18.48 24.21 8.17 
 
 
Figure 17: The cytotoxicity assay of PBD analogs 1, 2, 5 and 7 against SKBR-3, MCF-7, 
SKMEL-2, CaCo 2, HCT 116 and Mia Paca cell lines.  
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The MTT Assay works by adding 5-diphenyl-tetrazolium bromide (MTT) to a solution of 
cancer cells; the cells that are alive will metabolize the MTT solution, and produce formazan 
crystal (Scheme 13). The formazan crystals are then dissolved into solution, and their optical 
density is measured at 570 nm using a spectrophotometer. There is a direct correlation between 
the optical density of the formazan crystals and the number of viable cells left in solution. 
N
N N
N
N
S
Br
Mitochondrial Reductase
N
H
N
S N
N
N
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)
(E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan (Formazan)
 
Scheme 13: Metabolism of MTT by live cancer cells to form Formazan crystals. 
 
Enzyme Inhibition Kinetics 
Enzyme inhibition kinetics on the PBD analogs was performed using 20 mM MOPS 
buffer to ascertain the percentage inhibition and residue activity of the enzymes, TEM-1 and P99 
β-lactamases. 3 µL (final concentration = 90 nM) of enzymes was used for the assay. Percentage 
inhibition and residual activities of the enzymes after incubation with the PBD analogs 1−3 and 
7−9, in the presence of chromogenic substrate nitrocefin is shown in Tables 2 and 3 below. 
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Table 2: Residual Activity (%) and percent inhibition of TEM-1 after incubation with 
clavulanate and PBD derivatives for 5 minutes, 30 
o 
C in DMF (3%). 
Enzyme Inhibition Kinetics 
Conditions 
Vo ± SD (∆A, s
-1
) x 10
-4 Vi ± SD (∆A, s
-1
) x 
10
-4
 
Residual Activity 
(%) 
% 
Inhibition 
Clavulanate 
#
 1.3030 ± 1.7197 0.2912 ± 0.0042 22.35 77.65 
1 1.3030 ± 1.7197 0.8033 ± 0.00124 61.65 38.35 
2 1.3030 ± 1.7197 1.5274 ± 0.00177 100 0 
3 1.3030 ± 1.7197 1.7321 ± 0.00133 100 0 
7 1.3030 ± 1.7197 1.5671 ± 0.00108 100 0 
8 1.3030 ± 1.7197 1.3006 ± 0.00129 100 0 
9 1.3030 ± 1.7197 1.2179 ± 0.00171 93.50 6.22 
# Final concentration and volume of Clavulanate = 120 nM 
Final concentration & volume of Enzyme (TEM-1) = 3 µL (0.45 nM),  
Substrate (NCF) = 12 uL (100 µM), Triton X100 = 3 µL (0.1%),  
0.1 % BSA in MOPS buffer = 562 µL (0.02 mM, pH – 7.5),  
Inhibitor (in 3% DMF) = 20 µL (500 µM) 
 
Table 3: Residual Activity (%) and percent inhibition of P99 after incubation with clavulanate 
and PBD derivatives for 5 minutes, 30 
o 
C in DMF (3%). 
Enzyme Inhibition Kinetics Conditions Vo ± SD (∆A, s
-1) x 10-4 Vi ± SD (∆A, s
-1) x 10-4 Residual Activity (%) % Inhibition 
Clavulanate# 11.6110 ± 0.00679 10.1710 ± 0.07731 87.60 12.40 
1 11.6110 ± 0.00679 18.7340 ± 0.00125 100 0 
2 11.6110 ± 0.00679 16.4320 ± 0.00133 100 0 
3 11.6110 ± 0.00679 14.2330 ± 0.00101 100 0 
7 11.6110 ± 0.00679 24.0800 ± 0.03740 100 0 
8 11.6110 ± 0.00679 10.0680 ± 0.01720 86.71 13.29 
9 11.6110 ± 0.00679 17.6500 ± 0.01260 100 0 
#
 Final concentration and volume of Clavulanate = 120 nM 
Final concentration & volume of Enzyme (P99) = 3 µL (0.95 µM),  
Substrate (NCF) = 12 µL (100 µM), Triton X100 = 3 µL (0.1%),  
0.1 % BSA in MOPS buffer = 562 µL (0.02 mM, pH – 7.5),  
Inhibitor (in 3% DMF) = 20 µL (500 µM) 
 
Results from the enzyme kinetics show that all the PBD analogs had little or no inhibitory 
effects on both enzymes. PBD 1 had the highest percentage inhibition of 38.35 % against TEM-1 
β-lactamase but had no effect on P99 β-lactamase at a final concentration of 500 µM. Again, 
none of the remaining PBDs except compound 9, showed any inhibition at all. PBD 9 showed 
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percentage inhibition of 6.22 % against TEM-1 β-lactamase. Conversely, there was zero 
inhibitory efficacy of almost all the PBD analogs against P99 β-lactamase except for compound 
8, which exhibited a percent inhibition of 13.29 %. These observations are attributed to two 
possible reasons, the first being the poor solubility nature of the PBD analogs in the buffer 
solution. This makes them unavailable to the active site of the enzymes. Another reason may be 
the possibility of steric interferences from the 7-membered diazepine group (B-ring) and the 5-
membered pyrrolidine group (C-ring) of the PBD ring thus, making it impossible for the active 
part of the PBD analogs to interact with the active site of the enzymes. We envisage that if 
functional groups such as carboxylic (−COOH) and sulfate (−SO3H) are incorporated on the 
PBD analogs, their solubility in the buffer solution can further be enhanced. Thus, their 
inhibitory activities against the enzymes would be improved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
CHAPTER 3 
EXPERIMENTAL SECTION  
Materials and General Methods 
All reactions proceeded from the commercially available L-proline and isatoic anhydride. 
All reagents and solvents were obtained from commercial vendors and utilized without further 
purification unless stated.  
1
H NMR,
 13
C NMR, GC-MS and IR spectroscopy were the techniques used for the 
characterization of the synthesized compounds. JEOL-NMR Eclipse-400 MHz 
spectrophotometer provided all NMR data and spectra. The high frequency position conversion 
gave the different chemical shifts of all peaks in parts per million (ppm) with the coupling 
constants value (J) reported in Hz. The splitting patterns of resonance were also described as 
follows: singlet (s), doublet (d), doublet of doublet (dd), doublet of doublet of doublet (ddd), 
triplet (t), quartet (q), and multiplet (m). Genesis II FT-IR spectrometer was also used for all IR 
spectra. Cambridge Melt-Temp device provided melting point readings but without correction 
for the synthesized compounds. Shimadzu GC-MS 2010 System provided the relative 
abundances of the smaller ion fragments from the molecular ion of all compounds. Other 
common chromatographic techniques such as thin layer chromatography and column 
chromatography were also employed in the purification of all synthesized compounds. 
X-ray crystallographic analysis of compound 7 was also performed. A large colorless 
prism was cut (0.10 x 0.15 x 0.23 mm
3
) and centered on the goniometer of a Rigaku Oxford 
Diffraction Gemini E diffractometer operating with MoKα radiation.  The data collection 
routine, unit cell refinement, and data processing were carried out with the program 
CrysAlisPro.
105
 The Laue symmetry and systematic absences were consistent with the 
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monoclinic space groups I2 and I2/m.  As the sample was known to be enantiomerically pure, the 
acentric space group, I2, was chosen to give Z = 4 and Z’ = 1. The absolute configuration could 
not be determined from the anomalous dispersion effects. The structure was solved using 
SHELXS-2014
106
 and refined using SHELXL-2014
107
 via Olex2.
108
 The final refinement model 
involved anisotropic displacement parameters for non-hydrogen atoms and a riding model for all 
hydrogen atoms. 
 
Experimental Procedures 
(S)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione (1) 
Dilactam (1) was synthesized according to the previously reported methods with some 
modifications.
36
 A suspension of isotaic anhydride (10.0 g, 61.34 mmol) and L-proline (7.06 g, 
61.34 mmol) in N,N-dimethylformamide (DMF) (50 mL) was heated to 155 ˚C for 5 h. After 
cooling to room temperature, the solvent was removed in vacuo and the residue was taken up in 
water. The precipitate was collected and dried to give an off-white solid. Recrystallization from 
Acetone/DMF (10:1 v/v) afforded 10.87 g (82%) of pure compound 1 as off-white crystals. 
Yield: 82.0%; m.p: 223−225
 o
C;	


 = + 512 
o 
(c 0.5, MeOH); 
1
H-NMR (400 MHz, DMSO-
d6): δ = 1.80 (d, J = 9.9 Hz, 1H), 1.85−2.07 (m, 2H), 3.39−3.52 (m, 1H), 3.51−3.67 (m, 1H), 
4.02−4.21 (m, 1H), 7.07−7.17 (m, 1H), 7.17−7.27 (m, 1H), 7.51 (ddd, J = 8.6, 6.8, 1.3 Hz, 1H), 
7.78 (dd, J = 7.9, 1.6 Hz, 1H), 10.52 (s, 1H); 
13
C-NMR (100 MHz, DMSO-d6): δ = 23.6 (C-2), 
26.3 (C-1), 47.4 (C-3), 56.8 (C-11a), 121.8, 124.4, 127.1, 130.8, 132.6, 136.9, 165.0 (CO), 171.3 
(CO); IR (KBr); 3222 (N-H), 3206, 2955, 2918, 2850, 1691 (C=O), 1680 (C=O), 1621, 1551, 
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1536, 1479, 1443, 1412, 1385, 1285, 1259, 1179, 759, 701, 615; GC-MS (70 eV) m/z (%): 216 
(10) [M
+
], 119 (14), 92 (20), 70 (100), 64 (10).  
 
 
(S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (2) 
 A mixture of compound 1 (21.60 g, 100 mmol) and Lawesson’s reagent (20.2 g, 50 
mmol) in THF (400 mL) was stirred over night at room temperature. Evaporation of solvent in 
vacuo gave a crude solid yellow residue. The solid was washed with toluene and further washed 
with cold toluene to afford 20.2 g (87%) of pure compound 2 as yellow solid.
36,100
 Yield: 87.0%; 
m.p: 272−274 
o
C
 
; 
25

 = + 762 
o 
(c 0.5, CHCl3); 
1
H-NMR (400 MHz, DMSO-d6): δ = 
1.83−1.98 (m, 1H), 1.98−2.15 (m, 2H), 2.88 (d, J = 5.9 Hz, 1H), 3.31−3.51 (m, 3H), 3.53−3.60 
(m, 1H), 4.28 (d, J = 6.2 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.32−7.39 (m, 1H), 7.58 (td, J = 7.7, 
1.2 Hz, 1H), 7.83 (dd, J = 7.7, 1.5 Hz, 1H); 
13
C-NMR (100 MHz, DMSO-d6): δ = 23.2 (C-2), 
29.5 (C-1), 47.4 (C-3), 60.3 (C-11a), 122.3, 126.2, 128.3, 130.8, 132.7, 137.0, 164.7 (CO), 202.5 
(CS); IR (KBr): 3125 (N-H), 3094, 3063, 3024, 2974, 1620 (C=O), 1579, 1523, 1478, 1452, 
1418, 1381, 1272, 1193, 1166, 1145, 1103, 1069, 1055, 887, 833, 817, 786, 755, 695, 664, 625; 
GC-MS (70 eV) m/z (%): 232 (7) [M
+
], 108 (6), 70 (100), 68 (6). 
 
(S,E)-11-(propylimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-
one (3) 
To a stirred suspension of compound 2 (5.80 g, 25.0 mmol) and propylamine (20 mL) 
was added HgCl2 (7.14 g, 26.25 mmol) at 60 ˚C. The mixture was stirred for further 1 h at this 
temperature. After cooling to room temperature, the mixture was filtered through a plug of celite 
69 
 
and eluted with dichloromethane (CH2Cl2).
36
 The filtrate was washed with saturated Na2S2O3 
and after extraction with CH2Cl2, the combined organic layers were dried over magnesium 
sulfate (MgSO4), filtered, and the solvent and excess amine were evaporated under reduced 
pressure. The crude solid was purified by recrystallization in nitromethane to afford 5.64 g (88%) 
of pure compound 3 as colorless crystals. Yield: 88.0%; m.p: 159−161 
o
C;	
25

 = + 1106 
o 
(c 
0.5, CHCl3); 
1
H-NMR (400 MHz, CDCl3): δ = 0.98 (t, J = 7.5 Hz, 3H), 1.48−1.72 (m, 3H), 2.03 
(q, J = 8.9 Hz, 1H), 2.12 (d, J = 7.0 Hz, 1H), 2.18−2.29 (m, 2H), 3.38 (d, J = 4.8 Hz, 2H), 
3.50−3.64 (m, 1H), 3.82−3.93 (m, 1H), 4.03 (t, J = 4.9 Hz, 1H), 4.69 (s, 1H), 7.02−7.13 (m, 2H), 
7.38 (ddd, J = 8.6, 6.8, 1.3 Hz, 1H), 7.92 (dd, J = 7.7, 1.5 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3): 
δ = 11.7 (CH3), 22.3 (CH2), 23.9 (CH2), 26.8 (C-2), 43.3 (C-1), 46.5 (C-3), 54.4 (C-11a), 122.2, 
126.5, 126.9, 130.1, 131.6, 146.7, 156.2 (C-N), 166.8 (CO); IR (KBr): 3851, 3798, 3745, 3356 
(N-H), 3319 (N-H), 3287, 3061, 2941, 2880, 2815, 2359, 2328, 1826, 1791, 1731, 1605 (C=O), 
1554, 1531, 1506, 1456, 1406, 1383, 1336, 1256, 1215, 1150, 1096, 1067, 1035, 991, 918, 835, 
761, 703, 635; GC-MS (70 eV) m/z (%): 257 (21) [M
+
], 146 (23), 119 (23), 90 (21), 70 (100). 
  
5,6-Dihydro-4H-3-thia-6a,11b-diazabenzo[g]cyclopenta[e]azulene-1,7-dione (4) 
To a solution of compound 2 (0.464 g, 2.0 mmol) in anhydrous THF (40 mL) was added 
freshly distilled α-bromoacetyl chloride (0.39 g, 2.4 mmol). The mixture was stirred for 15 h at 
room temperature under nitrogen and then quenched by addition of saturated sodium bicarbonate 
(NaHCO3) (20 mL). After extraction with chloroform (2 × 20 mL), the combined organic layers 
were dried over Na2SO4, and the solvent was removed under reduced pressure. The crude residue 
was subjected to flash silica gel column chromatography using EtOAc/Hexane (4:1 v/v) as eluent 
and the solvent was evaporated under reduced pressure to give crude yellow solids.
36
 The crude 
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solid was purified by recrystallization from Ethanol/Water mixture to afford 0.20 g (75%) of 
pure compound 4 as yellow needle-like crystals. Yield: 75.0%; m.p: 165−167 
o
C; 
1
H-NMR (400 
MHz, CDCl3): δ = 1.98−2.05 (m, 2H), 2.67 (t, J = 8.0 Hz, 2H), 3.83 (s, 2H,), 3.90−3.94 (m, 
2H,), 7.28−7.32 (m, 1H), 7.44 (dd, J = 8.2, 1.0 Hz, 1H), 7.51−7.55 (m, 1H), 8.00 (dd, J = 8.0, 
1.6 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3): δ = 20.8 (C-5), 31.1 (C-4), 35.8 (C-2), 50.1 (C-6), 
115.5, 124.3, 124.9, 127.2, 128.5, 133.3, 133.6, 138.9, 165.4 (CO), 172.7 (CO); IR (KBr): 3398, 
3357, 3282, 2944, 2880, 2790, 2419, 2385, 2350, 2323, 1856, 1818, 1779, 1724, 1690, 1582, 
1482, 1404, 1384, 1358, 1334, 1217, 1126, 1092, 871, 835, 776, 708, 659, 636. 
 
(S,E)-11-(hydroxyimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-
one (5) 
To a solution of compound 2 (1.16 g, 5.0 mmol) in ethanol (30 mL) was added the 
hydroxylamine hydrochloride (0.417 g, 6.0 mmol) and potassium carbonate (2.20 g, 16.0 mmol). 
The light yellow mixture was stirred for 24 h at room temperature, where upon the mixture 
decolorized and H2S was released. After extraction with dichloromethane (100 mL) and washed 
with water (60 mL), the organic layer was further washed with brine, dried over sodium sulfate 
(Na2SO4), filtered and the solvent was removed in vacuo. The crude residue was recrystallized 
from nitromethane to afford 0.95 g (82%) of pure compound 5 as off-white crystals. Yield: 
82.0%; m.p: 150−153
 o
C;	


 = + 488 
o 
(c 0.5, CHCl3); 
1
H-NMR (400 MHz, CDCl3): δ = 1.68 
(d, J = 11.7 Hz, 1H), 1.89−2.19 (m, 4H), 2.59−2.73 (m, 1H), 3.57−3.74 (m, 1H), 3.76−3.86 (m, 
1H), 4.33 (dd, J = 7.5, 2.0 Hz, 1H), 6.90 (d, J = 7.3 Hz, 1H), 7.09−7.18 (m, 1H), 7.39−7.46 (m, 
1H), 7.76 (s, 1H), 7.93 (dd, J = 7.9, 1.6 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3): δ = 23.2 (C-2), 
25.9 (C-1), 47.4 (C-3), 54.4 (C-11a), 120.5, 123.5, 125.8, 131.6, 132.6, 136.9, 151.2, 166.2 
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(CO); IR (KBr): 3788, 3716, 3281, 2965, 2911, 2878, 2806, 2351, 1724, 1689, 1658, 1612, 1573, 
1552, 1530, 1480, 1453, 1425, 1396, 1273, 1227, 1201, 1162, 1108, 1040, 997, 957, 933, 884, 
847, 807, 787, 756, 701, 663; GC-MS (70 eV) m/z (%): 231 (20) [M
+
], 144 (37), 90 (35), 70 
(100). 
 
(S,E)-11-hydrazono-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one 
(6) 
To a solution of compound 2 (1.16 g, 5.0 mmol) in ethanol (20 mL) was added 98% 
hydrazine monohydrate (0.75 g, 15.0 mmol) and stirred for 15 h at room temperature. The 
solvent was removed in vacuo and the residue was taken up in water. The precipitate was 
collected, dried and washed with diethyl ether to afford 1.14 g (99%) of compound 6 as off-white 
solid.
103
 Yield: 99.0%; m.p: 178−180
 o
C;	


 = + 552 o (c 0.5, MeOH);  1H-NMR (400 MHz, 
CDCl3): δ = 1.61−2.08 (m, 4H), 2.65−2.82 (m, 1H), 3.57−3.69 (m, 1H), 3.71−3.84 (m, 1H), 
4.17−4.30 (m, 1H), 6.85 (d, J = 8.1 Hz, 1H), 7.09 (t, J = 7.7 Hz, 1H), 7.32−7.40 (m, 1H), 7.90 
(dd, J = 7.9, 1.3 Hz, 1H); 
13
C-NMR (100 MHz, CDCl3): δ = 23.4 (C-2), 26.1 (C-1), 47.3 (C-3), 
55.5 (C-11a), 119.7, 123.0, 125.4, 131.5, 132.5, 137.8, 152.2, 166.2 (CO); IR (KBr): 3484, 3282, 
3240, 3161, 2967, 2949,2871, 2814, 2422, 2358, 2336, 1957, 1854, 1784, 1766, 1726, 1689, 
1658, 1619, 1563, 1539, 1529, 1479, 1442, 1384, 1323, 1272, 1202, 1076, 943, 903, 825. 
 
(S)-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine-
3,9(2H)-dione (7) 
A solution of compound 6 (0.69 g, 3.0 mmol) and 1,1-carbonyldiimidazole (3.89 g, 24.0 
mmol) in dioxane (25 mL) was refluxed for 24 h. The solvent was removed in vacuo and the 
72 
 
crude product was purified by flash gel column chromatography using gradient elution. The 
ratios of solvent mixture used were EtOAc/Hexane (1:1, 2:1, 4:1 v/v) and a final elution with 
only Ethyl acetate (EtOAc). Recrystallization from EtOAc/Hexane (4:1 v/v) afforded 0.76 g 
(99%) of pure compound 7 as white crystals. Yield: 99.0%; m.p: 238−240
 o
C;	


 = + 136 o (c 
= 0.5, DMSO); 
1
H-NMR (400 MHz, CDCl3): δ = 1.99−2.22 (m, 2H), 2.23−2.37 (m, 1H), 2.86 
(ddd, J = 16.3, 6.8, 3.7 Hz, 1H), 3.64−3.75 (m, 1H), 3.81−3.92 (m, 1H), 4.53 (dd, J = 8.4, 3.3 
Hz, 1H), 7.42−7.51 (m, 1H), 7.59−7.67 (m, 1H), 7.90−7.98 (m, 1H), 8.03 (dd, J = 7.9, 1.6 Hz, 
1H), 9.90 (s, 1H); 
13
C-NMR (100 MHz, CDCl3): δ = 23.5 (C-2), 26.0 (C-1), 47.7 (C-3), 51.7 (C-
11a), 123.0, 127.8, 129.0, 130.1, 131.9, 132.3, 153.9 (CO), 164.7 (CO); IR (KBr): 3435, 3375, 
3183, 3091, 3000, 2909, 2878, 2814, 2326, 1711, 1611, 1574, 1490, 1466, 1412, 1343, 1285, 
1239, 1202, 1167, 1118, 1072, 1024, 979, 926, 912, 825, 786, 758, 709, 656, 616; GC-MS (70 
eV) m/z (%): 256 (60) [M
+
], 102 (26), 90 (38), 43 (100). 
 
(13aS)-3-mercapto-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4 -
c][1,4]diazepin-9-one (8) 
A solution of compound 6 (0.23 g, 1.0 mmol) and 1,1-thiocarbonyldiimidazole (1.42 g, 
8.0 mmol) in dioxane (20 mL) was refluxed for 24 h. The solvent was removed in vacuo and the 
crude product was purified by flash gel column chromatography using gradient elution. The 
ratios of solvent mixture used were Acetone/Hexane (10:1, 20:1 v/v). Recrystallization from 
EtOAc/Hexane (4:1 v/v) afforded 0.217 g (80%) of pure compound 8 as brown crystals. Yield: 
80.0%; m.p: >230
 o
C (dec.);	
25

 = + 37.5 
o 
(c 0.4, CHCl3); 
1
H-NMR (400 MHz, CDCl3): δ = 
1.62−1.99 (m, 1H), 2.03−2.28 (m, 2H), 2.29−2.45 (m, 1H), 2.89 (tt, J = 9.9, 3.4 Hz, 1H), 
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3.63−3.78 (m, 1H), 3.81−3.97 (m, 1H), 4.55 (dd, J = 8.4, 2.9 Hz, 1H), 7.50−7.60 (m, 1H), 
7.63−7.77 (m, 1H), 8.04 (dd, J = 7.7, 1.5 Hz, 1H), 8.39 (d, J = 8.1 Hz, 1H); 
13
C-NMR (100 
MHz, DMSO-d6): δ = 23.6 (C-2), 26.7 (C-1), 47.5 (C-3), 51.6 (C-11a), 126.2, 129.1, 130.6, 
130.8, 131.2, 131.4, 153.1, 164.0 (CO), 167.7 (CS); IR (KBr): 3735, 3280, 3174, 3127, 3096, 
3060, 2989, 2944, 2880, 2827, 2415, 2359, 2331, 1958, 1760, 1723, 1686, 1611, 1542, 1488, 
1410, 1344, 1310, 1286, 1216, 1112, 1043, 1003, 973, 921, 892, 876, 825, 756, 704, 664, 638, 
622, 610; GC-MS (70 eV) m/z (%): 272 (100) [M
+
], 116 (23), 90 (34), 70 (33). 
 
(S)-7-nitro-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione (9) 
To a solution of concentrated sulfuric acid (50 mL) at 0 
o
C was compound 1 (6.48 g, 30.0 
mmol) added. After being stirred for 10 min, concentrated nitric acid (7 mL) was added. The 
reaction mixture was stirred at 0 
o
C for 2 h and quenched with ice water. The precipitated 
product was filtered, washed with water and dried to give yellow crude solid.
104
 Recrystallization 
from MeOH afforded 6.0 g (77%) of pure compound 9 as brown yellow crystals. Yield: 77.0%; 
m.p: 266−268
 o
C;	


 = + 744 o (c 0.5, CHCl3); 1H-NMR (400 MHz, CDCl3): δ = 1.59−2.40 
(m, 3H), 2.79 (s, 1H), 3.40−3.98 (m, 2H), 4.13 (d, J = 6.6 Hz, 1H), 8.31 (d, J = 7.7 Hz, 1H), 
8.89 (s, 1H), 9.39 (s, 1H); 
13
C-NMR (100 MHz, CDCl3): δ = 23.5 (C-2), 26.4 (C-1), 47.9 (C-3), 
56.9 (C-11a), 122.0, 127.3, 127.4, 127.7, 140.3, 144.5, 163.5 (CO), 171.0; IR (KBr): 3362, 3289, 
3244, 3184, 3136, 2944, 2878, 2719, 1900, 1852, 1816, 1704, 1692, 1640, 1630, 1587, 1529, 
1484, 1442, 1384, 1342, 1281, 1260, 1201, 1154, 1127, 1084, 1056, 1025, 997, 919, 862, 773, 
749, 664.  
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CHAPTER 4 
CONCLUSION AND FUTURE WORK 
Conclusion 
In this project, PBD dilactam (1) (formed from the cyclocondensation of commercially 
available isatoic anhydride with L-proline in DMF for 5 hours) was used as the starting material 
to synthesize all the various derivatives of PBD. MTT Assay was employed to test the in vitro 
cytotoxicity of PBD analogs 1, 2, 5 and 7 on cancer cell lines including MCF-7 (Breast), SKBR-
3 (Breast), SKMEL-2 (Melanoma), CaCo 2 (Colon) and Mia Paca (Pancreatic). These 
compounds decreased the cell viability of MCF-7 by roughly 20% however, only 1 and 5 had 
any effect on the SKMEL-2 cell lines. The inhibitory efficacy of PBD analogs 1−3 and 5−9 were 
also tested against TEM-1 and P99 Serine class A and C β-lactamases.  
The PBD derivatives were: (S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (2), (S)-11-(propylamino)-1,2,3,11a-tetrahydro-5H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (3), 5,6-Dihydro-4H-3-thia-6a,11b-
diazabenzo[g]cyclopenta[e]azulene-1,7-dione (4) (S,E)-11-(hydroxyimino)-1,2,3,10,11,11a-
hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (5), (S,E)-11-hydrazono-
1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (6), (S)-11,12,13,13a-
tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine-3,9(2H)-dione (7), 
(13aS)-3-mercapto-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4 -
c][1,4]diazepin-9-one (8) and (S)-7-nitro-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-5,11(10H)-dione (9). 
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Results from the enzyme kinetics showed that all the PBD analogs had little or no 
inhibitory effects on both TEM-1 and P99 Serine A and C β-lactamases. One of the possible 
reasons being the poor solubility of the PBDs in the MOPs buffer solution thus, making the 
active site unavailable to the active site of both enzymes. Again, steric interference due to the 
bulkiness of the PBDs prevents effective interactions with the enzymes. 
Future Work 
We would focus on introducing functional groups such as carboxylic acid (−COOH) and 
sulfate (−SO3H) on the PBD rings in order to further enhance the solubility of the PBD analogs 
for better interactions with the enzymes. Also, the inhibitory efficacy of the synthesized PBD 
analogs would be tested on other enzymes such as Angiotensin-converting enzymes (ACE), 
implicated in diseases and infections. 
Finally, synthesis and in vitro evaluation of novel PBDs analogous to anthramycin but with 
minimal or no cytotoxicity on normal human cell would be another area of focus. 
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Appendix A6: GC-MS Spectrum for Compound 1 
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Appendix A7: IR Spectrum for Compound 1 
N
N
H O
O
H
1  
 
 
 
 
 
97 
 
Appendix B1: 
1
H NMR Spectrum for Compound 2 in DMSO-d6 
N
N
H S
O
H
2  
 
 
 
 
 
98 
 
Appendix B2: 
1
H NMR Spectrum for Compound 2 in DMSO-d6 
N
N
H S
O
H
2  
 
 
 
 
 
99 
 
Appendix B3: 
1
H NMR Spectrum for Compound 2 in DMSO-d6 
N
N
H S
O
H
2  
 
 
 
 
 
100 
 
Appendix B4: 
13
C NMR Spectrum for Compound 2 in DMSO-d6 
N
N
H S
O
H
2  
 
 
 
 
 
101 
 
Appendix B5: C DEPT-135 NMR Spectrum for Compound 2 in DMSO-d6 
N
N
H S
O
H
2  
 
 
 
 
 
102 
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Appendix F5: GC-MS Spectrum for Compound 7  
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Appendix F6: IR Spectrum for Compound 7  
N
N
O
H
N
H
N
O
7  
 
 
 
 
129 
 
Appendix F7: Selected Torsional Angles [
o
] for the X-ray Crystal Structure of Compound 7  
 
C9-N1-C1-O1 -172.9(1) N3-N4-C10-N2 -2.2(2) N2-C8-C9-C11 173.6(1) 
C9-N1-C1-C2 6.0(2) H4A-N4-C10-O2 13(2) N3-C8-C9-N1 -121.4(2) 
C13-N1-C1-O1 -0.0(2) H4A-N4-C10-N2 -168(2) N3-C8-C9-H9 117.2 
C13-N1-C1-C2 178.9(1) O1-C1-C2-C3 33.8(2) N3-C8-C9-C11 -6.3(2) 
C1-N1-C9-C8 -68.2(2) O1-C1-C2-C7 -142.4(2) N1-C9-C11-H11A 142.8 
C1-N1-C9-H9 53.2 N1-C1-C2-C3 -145.2(1) N1-C9-C11-H11B -96 
C1-N1-C9-C11 171.6(1) N1-C1-C2-C7 38.6(2) N1-C9-C11-C12 23.4(1) 
C13-N1-C9-C8 118.2(1) C1-C2-C3-H3 3 C8-C9-C11-H11A 24.6 
C13-N1-C9-H9 -120.3 C1-C2-C3-C4 -176.9(1) C8-C9-C11-H11B 145.9 
C13-N1-C9-C11 -2.0(2) C7-C2-C3-H3 179.6 C8-C9-C11-C12 -94.8(1) 
C1-N1-C13-C12 165.9(1) C7-C2-C3-C4 -0.4(2) H9-C9-C11-H11A -98.9 
C1-N1-C13-H13A 46.8 C1-C2-C7-N2 -2.5(2) H9-C9-C11-H11B 22.4 
C1-N1-C13-H13B -75 C1-C2-C7-C6 177.0(1) H9-C9-C11-C12 141.7 
C9-N1-C13-C12 -20.3(2) C3-C2-C7-N2 -178.7(1) C9-C11-C12-H12A 83.4 
C9-N1-C13-H13A -139.4 C3-C2-C7-C6 0.9(2) C9-C11-C12-H12B -155.1 
C9-N1-C13-H13B 98.8 C2-C3-C4-H4 180 C9-C11-C12-C13 -35.9(1) 
C8-N2-C7-C2 -43.6(2) C2-C3-C4-C5 0.0(2) H11A-C11-C12-H12A -36 
C8-N2-C7-C6 136.9(1) H3-C3-C4-H4 0 H11A-C11-C12-H12B 85.5 
C10-N2-C7-C2 149.1(1) H3-C3-C4-C5 -180 H11A-C11-C12-C13 -155.2 
C10-N2-C7-C6 -30.5(2) C3-C4-C5-H5 179.9 H11B-C11-C12-H12A -157.3 
C7-N2-C8-N3 -170.5(1) C3-C4-C5-C6 -0.1(2) H11B-C11-C12-H12B -35.8 
C7-N2-C8-C9 9.6(2) H4-C4-C5-H5 -0.1 H11B-C11-C12-C13 83.5 
C10-N2-C8-N3 -1.1(2) H4-C4-C5-C6 179.9 C11-C12-C13-N1 34.1(1) 
C10-N2-C8-C9 179.0(1) C4-C5-C6-H6 -179.5 C11-C12-C13-H13A 153.2 
C7-N2-C10-O2 -9.5(3) C4-C5-C6-C7 0.6(2) C11-C12-C13-H13B -85 
C7-N2-C10-N4 171.2(1) H5-C5-C6-H6 0.6 H12A-C12-C13-N1 -85.2 
C8-N2-C10-O2 -178.8(2) H5-C5-C6-C7 -179.4 H12A-C12-C13-H13A 33.9 
C8-N2-C10-N4 1.9(2) C5-C6-C7-N2 178.6(1) H12A-C12-C13-H13B 155.7 
C8-N3-N4-H4A 169(2) C5-C6-C7-C2 -1.0(2) H12B-C12-C13-N1 53.3 
C8-N3-N4-C10 1.6(2) H6-C6-C7-N2 -1.4 H12B-C12-C13-H13A -87.6 
N4-N3-C8-N2 -0.3(2) H6-C6-C7-C2 179.1 H12B-C12-C13-H13B 34.2 
N4-N3-C8-C9 179.6(1) N2-C8-C9-N1 58.5(2)   
N3-N4-C10-O2 178.5(2) N2-C8-C9-H9 -62.9   
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Appendix G6: C DEPT-135 NMR Spectrum for Compound 8 in DMSO-d6 
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Appendix G7: GC-MS Spectrum for Compound 8 
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Appendix G8: IR Spectrum for Compound 8 
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Appendix H5: C DEPT-135 NMR Spectrum for Compound 9 in CDCl3 
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Appendix H6: IR Spectrum for Compound 9 
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